Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JEUPG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Sacituzumab-Deruxtecan
|
|||||
| Synonyms |
WO2022068878A1
Click to Show/Hide
|
|||||
| Organization |
Duality Biologics
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Hypopharyngeal squamous cell carcinoma [ICD11:2B6D.0]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.18
|
|||||
| Structure |
|
|||||
| Antibody Name |
Sacituzumab
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.